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The term “encephalopathy of prematurity” encompasses not only the acute brain injury
[such as intraventricular hemorrhage (IVH)] but also complex disturbance on the infant’s
subsequent brain development. In premature infants, the most frequent recognized source
of brain injury is IVH and periventricular leukomalacia (PVL). Furthermore 20–25% infants
with birth weigh less than 1,500 g will have IVH and that proportion increases to 45% if the
birth weight is less than 500–750 g. In addition, nearly 60% of very low birth weight new-
borns will have hypoxic-ischemic injury.Therefore permanent lifetime neurodevelopmental
disabilities are frequent in premature infants. Innovative approach to prevent or decrease
brain injury in preterm infants requires discovery of biomarkers able to discriminate infants
at risk for injury, monitor the progression of the injury, and assess efficacy of neuropro-
tective clinical trials. In this article, we will review biomarkers studied in premature infants
with IVH, Post-hemorrhagic ventricular dilation (PHVD), and PVL including: S100b, Activin
A, erythropoietin, chemokine CCL 18, GFAP, and NFL will also be examined. Some of the
most promising biomarkers for IVH are S100β and Activin. The concentrations of TGF-β1,
MMP-9, and PAI-1 in cerebrospinal fluid could be used to discriminate patients that will
require shunt after PHVD. Neonatal brain injury is frequent in premature infants admitted
to the neonatal intensive care and we hope to contribute to the awareness and interest in
clinical validation of established as well as novel neonatal brain injury biomarkers.
Keywords: biomarkers, intraventricular hemorrhage, post-hemorrhagic ventricular dilation, periventricular
leukomalacia, brain injury
INTRODUCTION
Increasing rates of survival of extremely premature infants has
produced a shift of paradigms from “survival” to “prevention of
morbidity” including brain injury. The discovery and validation of
neonatal biomarkers of brain injury is a key step in the evolution
of neonatal neuroprotection. These markers may enable the clin-
icians to screen infants for brain injury, monitor the progression
of disease, identify injured brain regions, and assess the efficacy of
neuroprotective strategies procedures in clinical trials. Currently,
clinicians do not use biomarkers to care for neonates with brain
injuries. This review will examine potential biomarkers for the
most common brain injuries in premature infants, such as intra-
ventricular hemorrhage (IVH), post-hemorrhagic hydrocephalus,
and periventricular leukomalacia (PVL).
BIOMARKERS OF INTRAVENTRICULAR HEMORRHAGE
One major source of long-term neurologic deficits in premature
neonates is the injury to the germinal matrix and the subventric-
ular zone (Volpe, 2009). These injuries produce IVH. Approxi-
mately 20–25% of premature infants weighing less than 1,500 g
Abbreviations: aEEG, amplitude integrated electroencephalogram; CPK-BB, arain-
type creatine phosphokinase; CSF, cerebrospinal fluid; CCL18, chemokine ligand
18; CRP, C-reactive protein; EPO, erythropoietin; GA, gestational age; IVH, intra-
ventricular hemorrhage; MMP-9, matrix metalloproteinase-9; PVL, periventricu-
lar leukomalacia; PAI-1, plasminogen activator inhibitor 1; TGF-β1, transforming
growth factor beta 1; TGF-β2, transforming growth factor beta-2; UA, uric acid.
will have an IVH (Volpe, 2008). The risk of IVH is inversely
related to gestational age and birth weight. Forty-five percent of
infants weighing 500–750 g develop IVH (Wilson-Costello et al.,
2005). Immature blood vessels in the germinal matrix, a highly
vascular region of the brain, combined with poor tissue vascu-
lar support, predispose premature infants to hemorrhage (Volpe,
2009). Clinical presentation of IVH can range from an acute
newborn deterioration of the newborn (with apnea, pallor, acido-
sis, hypotension, bulging fontanel, seizures, and decreased muscle
tone) to a “clinically silent syndrome” (no symptoms). Biomarkers
that hold promise in predicting which neonates may suffer an IVH
and long-term deficits will be reviewed.
The protein S100 family encompasses many calcium sensor pro-
teins that modulate biological activity via calcium binding (Ikura,
1996). In particular, S100β (a homodimer of the subunit beta)
protein is primarily synthesized in the brain by astrocytes and is
quickly released from the brain into the blood when the blood-
brain-barrier is disrupted (Kapural et al., 2002; Marchi et al., 2003).
In the central nervous system S100β protein is predominantly
concentrated in the astroglial cell population (Heizmann, 1999).
However, reports of extra cranial sources of S100β, especially from
adipose and muscle tissue, may confound its interpretation in
the clinical setting (Otto et al., 2000; Bloomfield et al., 2007).
S100β has a dual function depending on its concentrations. At
nanomolar physiological concentrations, S100β is neurotrophic
(Haglid et al., 1997). However, when S100β is overexpressed (in
micromolar concentrations), it enhances neuroinflammation and
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neuronal apoptosis (Van Eldik and Wainwright, 2003). Recently an
excess of S100β and amyloid precursor protein has been linked to
impaired neurogenesis (due to the gliocentric shift of neural prog-
enitor cells) in Down syndrome (Bouvier et al., 2011; Lu et al.,
2011).
S100B has been well studied in the pediatric population.
Immunoassay kits are commercially available and can detect S100β
in many biological fluids such as urine, blood, CSF, amniotic fluid,
saliva, and milk (Gazzolo and Michetti, 2010; Gazzolo et al., 2010).
Furthermore, reference ranges are available for the pediatric pop-
ulation including preterm and term healthy newborns (Gazzolo
et al., 2007; Bouvier et al., 2011). In general, healthy children have
higher serum S100β concentrations than adults and the concentra-
tions decline over time, especially during the first 6 months of life
(Bouvier et al., 2011). Similarly, urinary S100β concentrations are
higher in premature infants than in term newborns and steadily
decrease with advancing gestational age (Gazzolo et al., 2007).
Gazzolo et al. (2006) reported that maternal blood concentra-
tions of S100β >0.72 mcg/L were able to predict neonatal IVH
with 100% sensitivity, 99% specificity, and 0.999 area under the
ROC curve. However, measurements of serum S100β during preg-
nancy could be affected by multiple factors, such as gestational
age, intrauterine growth, prenatal steroids use, twin gestation, and
trisomy 21 (Gazzolo et al., 2003a,b; Sannia et al., 2010).
Premature infants with high concentrations of S100β in urine
have higher mortality than matched controls for gestational age
and weight with a positive predictive value of 78% and a negative
predictive value of 100% (Gazzolo et al., 2005). S100β also plays a
role in predicting IVH in neonates. Newborns that developed IVH
have elevated S100β concentrations in blood and urine (Gazzolo
et al., 1999, 2001). In addition, the urine S100β level correlates
with the degree of IVH (Gazzolo et al., 2001). Taken together,
these publications support the hypothesis that early brain injury
may be responsible for a continuous release of S100β protein from
the CNS into the systemic circulation and urine. Because IVH is
more frequent in very small infants with birth weight 500–750 g,
biomarkers that do not require blood samples are more clinical
relevant. Therefore, one major advantage of S100β is that it can
be measured in urine. In addition, there are commercially avail-
able kits to measure S100β. We believe that the next step in the
validation of S100β as biomarker of IVH would be studies that
incorporate its association with brain injury assessed by brain MRI
and long-term functional outcomes.
Activin is another proposed biomarker for IVH. Activin, a
member of the transforming growth factor-β superfamily, is a
trophic factor that regulates differentiation and proliferation of
neurons and a wide variety of cells (Florio et al., 2007). Activin
receptors are highly expressed in neuronal cells and neuronal
activity up-regulates activin mRNA expression (He et al., 2012).
In animal models, Activin is neuroprotective during excitotoxic
brain injury (Mukerji et al., 2007). In transgenic mice, activin
regulates spine formation, behavioral activity, anxiety, adult neu-
rogenesis, late-phase long-term potentiation, and the maintenance
of long-term memory (Ageta et al., 2008; Zheng et al., 2009).
Florio et al. (2006) found that premature newborns that devel-
oped IVH had high concentrations of Activin A in blood samples
drawn during their first hour of life. In his cohort of 53 infants
<32 weeks gestational age, 21% developed IVH detected by serial
head ultrasound (HUS). Activin above 0.8 mcg/L predicted IVH
with 100% sensitivity of 100%, and 93% specificity (with positive
predictive value of 79%). Activin A is also increased in term new-
borns with moderate or severe asphyxia suggesting that activin is
released after neuronal (Florio et al., 2004). Activin A should be
validated in larger cohort of premature infants and correlated not
only with IVH diagnosed by HUS but also with term corrected
brain MRI (a more sensitive and specific brain injury detection).
Erythropoietin (EPO) is also a potential biomarker of IVH. EPO
and its receptor are expressed in astrocytes, neurons, and endothe-
lial brain cells (Marti, 2004). Bhandari published a prospective
pilot cohort study of cord blood concentration of EPO in 116
infants less than 34 weeks GA (Bhandari et al., 2011). In this
study, 25% infants had IVH diagnosed by serial HUS. Elevated
cord blood EPO levels were predictors of IVH even after correc-
tion for gestational age. In the same cohort, inflammatory markers
(such cord blood IL-6, pH, and early onset of neonatal sepsis) were
not associated with IVH. These results suggest that elevated cord
blood EPO may predict neonatal risk for IVH, independent of fetal
inflammatory status. EPO production is increased in response to
fetal hypoxia (Davis et al., 2003; Teramo and Widness, 2009). Thus,
elevated EPO in cord blood may indicate fetal hypoxic conditions
that lead to injury of the germinal matrix resulting in IVH. EPO is
attractive as a biomarker because it can be measured at birth and
the results are available the same day. Nevertheless it is important
to establish if high levels Epo correlate with functional outcomes.
Chemokine ligand 18 (CCL18) belongs to the CC-chemokine
family, is encoded in chromosome 17q11.2 and participates in the
lymphocytes homing and the primary immune response (Zlotnik
et al., 2006). As a result, inflammatory conditions may increase
levels of CCL18 (Schutyser et al., 2005). Preterm infants who
developed cerebral palsy have lower cord blood levels of CCL18
(Kaukola et al., 2004). Patients with traumatic brain injuries
have elevated CCL18 in biopsies of brain tissue (Chang et al.,
2010). In a prospective cohort study of 163 premature infants
(less than 32 weeks of gestation), Kallankari et al. (2010) ana-
lyzed 107 cord blood immunoproteins, 12 cytokines from the
peripheral blood, serial HUS in all newborns, and brain immuno-
histochemistry of chemokine receptors from the autopsies of 14
patients. Cord chemokine CCL18 robustly predicted the risk of
IVH grades II-IV and was not associated with chorioamnionitis
or funisitis. CCL18 receptor was detectable in the choroid plexus,
periventricular capillary endothelium, ependymal cells, and the
germinal matrix which may explain that high cord levels of CCL18
could be protective against IVH and brain injury by blocking the
action of agonistic ligands on CCR3, thereby inhibiting leukocyte
degranulation and inflammatory activation. Because CCL18 is an
inflammatory mediator, it may be a very sensitive but not specific
biomarker for IVH.
Uric acid (UA) is the end product of purine metabolism.
Because UA has poor solubility, continuous renal excretion is
necessary to avoid its toxic accumulation. High serum UA con-
centrations are expected when there are increase in production or
decrease in its excretion. During hypoxic-ischemic events, hypox-
anthine, a purine intermediate metabolite, accumulates. During
the reperfusion states, hypoxanthine is then converted to UA
(Perlman and Risser, 1998). Perlman and Risser (1998) reported
elevated concentrations of UA (during first 24 h) in premature
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infants that developed IVH and PVL. In support of these findings,
Aliefendioglu et al. (2006) found that high UA concentrations in
CSF were associated with a higher risk of IVH. However, other
study of low birth weight infants did not find association between
elevated UA in serum and IVH (Sysyn and Rozycki, 2003). UA has
conflicting results as brain injury biomarker.
Brain-type creatine phosphokinase (CPK-BB) is an enzyme
expressed in various cell types and catalyzes the conversion of
creatine to phosphocreatine (energy reservoir for cells that con-
sume ATP rapidly). Van de Bor et al. (1988) found that higher
serum CPK-BB during the first day of life was associated with
IVH detected by serial HUS. Nevertheless, the small number of
newborns with severe IVH limited the interpretation of the results
of this pilot study. In a later study, Amato et al. (1989) found
that only the CPK-BB values obtained during the first 6 h of life,
but not later, were associated with IVH. This early elevations of
CPK-BB concentration suggest association with prenatal events.
One plausible explanation is that during hypoxic-ischemic events,
brain cells deplete their ATP and increase CPK-BB concentrations
to obtain more phosphocreatine (other source of cell energy). In
our opinion, this biomarker shows limited predictability for brain
injury because it is not specific to brain injury and is only increased
for few hours.
IL-6 and C-reactive protein (CRP) are inflammatory markers,
therefore non-specific markers of brain injury. Sorokin et al. fol-
lowed a cohort of 475 asymptomatic pregnant women at risk for
preterm birth. He found that high maternal serum concentrations
of IL-6 and CRP were associated with increase risk of IVH in their
premature infants even after adjusting for gestational age (Sorokin
et al., 2010). Notably, 25 out of 30 neonates had grade I IVH. It is
possible maternal inflammatory markers reflect the fetal environ-
ment and therefore could be associated with brain pathology but
they are not specific for brain injury.
BIOMARKERS FOR POST-HEMORRHAGIC VENTRICULAR
DILATION
Following a large IVH, blood clots throughout the ventricular
system may block the channels for the reabsorption of cere-
brospinal fluid and the lateral ventricles enlarge producing Post-
hemorrhagic ventricular dilation (PHVD; Whitelaw and Aquilina,
2012). Overtime, the chronic inflammation, free iron, free rad-
icals, and the excessive intracranial pressure produce not only
ventricle enlargement but also progressive periventricular white
matter injury. Patients with PHVD have worse outcomes: 40%
develop cerebral palsy and 25% have multiple impairments (Ven-
triculomegaly trial group, 1994; Kennedy et al., 2001). Patients
with large amounts of blood clots in the ventricles have a higher
risk for shunt placement (Whitelaw, 2001; Whitelaw and Aquilina,
2012). Deciding when to intervene in patients with PHVD could
be a challenge in part due to the small size of the patient (often
between 1 and 2 kg) and complications related to drains. There is
no precise test that could help to determine when is the best time to
place a drain (external drain or shunt) to avoid secondary periven-
tricular brain damage (Davies et al., 2000; Whitelaw and Aquilina,
2012). The following biomarkers are associated with PHVD and
need for shunt:
Transforming growth factor beta 1 (TGF-β1) is released into
CSF after intraventricular bleeding and up-regulates the genes
to increase production of extracellular matrix (ECM) proteins
such as collagen and fibronectin (Whitelaw and Aquilina, 2012).
Excessive production of ECM could lead to blockage of CSF reab-
sorption. Therefore, TGF β1 could serve as a biomarker of PVHD.
Whitelaw et al. (1999) found higher concentrations of TGF β1
in CSF of preterm infants with PHVD than preterm controls.
Among the PHVD patients, those with highest TGF β1 concen-
trations had higher rate of shunt placement. TGFβ1> 6.5 ng/mL
in CSF was 80% sensitive and 78% specific to discriminate which
infants with PHVD would require a shunt. By contrast, Heep et al.
(2004) found that increased concentrations of TGFβ-1 in CSF did
not correlate with PHVD but correlated with white matter injury.
Lipina et al. (2010) reported that patients with PVHD with TGF
β-1> 2,396 pg/mL had a sensitivity of 79% and specificity of 80%
to predict which patients would not benefit of endoscopic third
ventriculostomy (surgery that allow CSF to leave the ventricular
system) and need shunt placement. Elevated TGF β-1 is associ-
ated with worse course of PHVD either because patient has higher
risk of shunt placement or white matter injury. Unfortunately, this
biomarker is only measured in CSF and need validation in larger
studies.
Transforming growth factor beta-2 (TGF-β2) is associated with
a decreased proliferation of neuronal precursors and induction
of cell death of oligodendrocytes. Chow et al. (2005) found that
in patients with PHVD, TGF β-2 in CSF was 20 times greater if
patients required shunt and it was associated with worse neu-
rodevelopment outcome at 15 months. It is possible that high
concentrations of TGF-β2 in CSF correlate with worse prognosis
due to its effects with neurons and oligodendrocytes. This potential
biomarker needs validation in larger cohort of patients.
Proteins of the matrix metallo-proteinases (MMPs) family are
involved in the breakdown of ECM proteins (Rosell et al., 2008).
Okamoto et al. (2008) found that MMP-9 in CSF was higher in
patients with PHVD than controls. Higher MMP-9 concentra-
tions possible reflect ongoing brain tissue remodeling in patients
with PHVD. Patients with PHVD that required a shunt had higher
MMP-9 levels than controls but lower MMP-9 concentrations than
PHVD patients without need for a shunt. A plausible explanation
for this finding is that patients with lower MMP-9 concentrations
could not degrade the amount of extracellular proteins produced
and end with CSF outflow obstruction requiring shunt placement.
Validation studies are necessary for this pilot report.
Plasminogen activator inhibitor 1 (PAI-1) is one of the main
inhibitors of fibrinolysis (physiological breakdown of blood clots;
Booth et al., 1988). Hansen et al. showed that CSF concentra-
tion of PAI-1 was highest in patients with PHVD compared with
neonates with IVH without PHVD (Hansen et al., 1997, 2000). It is
possible that neonates who develop IVH and have impaired blood
breakdown due to high concentrations of PAI-1 would develop
PHVD. This is promising biomarkers but needs more validation
studies.
Whitelaw et al. (2001) found that median neurofilament (NFL)
and glial fibrillary acidic protein (GFAP) concentrations in infants
with PHVD were 20–200 times higher than controls. In the same
study, patients with PHVD had four times higher S100 protein
in CSF than control patients and GFAP concentrations correlated
with death or disability. We think that NFL and GFAP are plausible
biomarkers of PHVD but they required CSF samples. Again, this
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Table 1 | Summary of biomarkers characteristics.
Biomarker Description Cell specificity Pathophysiology
S100β Protein that binds calcium and is
a major component of the
cytosol in various cell types
(Ikura, 1996)
Astroglial cells have a high concentration of
S100β (Heizmann, 1999). Other cells can
release S100β (Bloomfield et al., 2007)
Increased concentrations of S100β occur
predominantly after astrocyte death (Van
Eldik and Wainwright, 2003)
Activin A Trophic factor, member of the
transforming growth factor-β
superfamily (Florio et al., 2007)
Activin receptors are highly expressed in
neuronal cells (Florio et al., 2007)
Increased concentrations of Activin A
occur predominantly after neuronal
injury (Florio et al., 2006, 2007)
Erythropoietin Trophic factor and is synergistic
with other growth factors (Marti,
2004)
Produced mainly by interstitial fibroblasts in
the kidneys and placenta and hepatocytes in
the fetus (Davis et al., 2003). EPO and its
receptor are expressed throughout the brain in
glial cells, neurons, and endothelial cells
(Marti, 2004)
Increased concentrations of EPO occur
after hypoxic conditions (endogenous
mechanism neuronal protection; Marti,
2004; Teramo and Widness, 2009)
Chemokine CCL18 Member of the CC-chemokine
family (Zlotnik et al., 2006)
Monocytes and dendritic cells secrete CCL18.
CCL18 receptor is detectable in the choroid
plexus, periventricular capillary endothelium,
ependymal cells, and the germinal matrix
(Kallankari et al., 2010)
High concentrations of CCL18 blocks the
action of agonistic ligands on CCR3
(decreasing inflammatory response) and
could be protective factor for IVH (Chang
et al., 2010; Kallankari et al., 2010)
TGF-b1 Member of the transforming
growth factor-β superfamily (Pal
et al., 2012)
Main sources of TGF-β1 in the injured brain are
astrocytes and microglia but neurons can
produce it as well (Heinemann et al., 2012; Pal
et al., 2012). TGF-β1 released into CSF after
IVH, up-regulate the genes for extracellular
matrix (Whitelaw and Aquilina, 2012)
High concentrations of TGF- (β1 may
trigger excessive production of ECM
leading to blockage of CSF reabsorption,
therefore could serve as biomarker of
PVHD (Whitelaw et al., 1999)
MMP-9 Member of the proteins of the
matrix metallo-proteinases
(MMPs) family (Rosell et al.,
2008; Pal et al., 2012)
All cell types of the CNS are potential sources
of MMPs. MMP-9 is involved in the
breakdown of extracellular matrix proteins
(Okamoto et al., 2008; Rosell et al., 2008)
Higher concentrations of MMP-9 are
needed to degrade the extracellular
proteins after IVH. Lower MMP-9
concentrations in CSF of patients with
PVHD could predict patients that will
need shunt (Okamoto et al., 2008)
PAI-1 Main inhibitor fibrinolysis (Booth
et al., 1988)
PAI is mainly produced by vascular endothelial
cells, but also secreted by many other tissues
(hepatic, adipose, etc.). This protein that inhibit
tissue plasminogen activator and urokinase,
the activators of plasminogen (Booth et al.,
1988)
High concentrations of PAI-1 in CSF
could impaired blood removal
(fibrinolysis) after IVH, leading to PVHD
(Hansen et al., 1997, 2000)
GFAP and NFL Cytoskeletal intermediate and
median filament protein found in
the astrocytes (Mayer et al.,
1989; Eng and Ghirnikar, 1994;
Middeldorp and Hol, 2011)
Specific marker of differentiated astrocytes
(Middeldorp and Hol, 2011)
Higher concentrations of GFAP and NFL
in CSF are expected after astrocyte
death (Whitelaw et al., 2001)
Summary of potential biomarkers of brain injury including intraventricular hemorrhage (IVH), and post-hemorrhagic ventricular dilation (PHVD).
is promising pilot data but needs confirmation with large number
of patients.
BIOMARKERS OF PERIVENTRICULAR LEUKOMALACIA
Periventricular leukomalacia is a cerebral white matter injury
that occurs to some degree in 50% of neonates with birth
weights less than 1,500 g (Volpe et al., 2011). PVL is associ-
ated with a decrease in the volume of the cortex, thalamus, and
basal ganglia (Volpe et al., 2011). This injury likely account for
90% of the neurologic deficits, including cerebral palsy, cogni-
tive, behavioral, and attention deficits, that occurs in surviving
premature neonates. In addition, up to 50% of neonates with
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Table 2 | Most promising biomarkers and usefulness in neonatal brain injury.
Biomarker Fluids locations Change Associations (reference) Usefulness
S100β Urine, Blood, CSF ↑ IVH (Gazzolo et al., 1999, 2007, 2010) ++
Asphyxia and HIE (Gazzolo et al., 2001, 2005)
Activin A Blood ↑ IVH (Florio et al., 2006, 2007) ++
Asphyxia (Florio et al., 2004)
Epo Blood ↑ IVH (Bhandari et al., 2011) ++
CCL18 Blood ↓ Lower concentrations in neonates that developed IVH (Kallankari et al., 2010) ++
TGF-β1 CSF ↑ PHVD (Whitelaw et al., 1999, 2001; Lipina et al., 2010) +
↑ PHVD patients that that required shunt (Whitelaw et al., 1999) +++
TGF-β2 CSF ↑ PHVD (Chow et al., 2005) +
PHVD patients that develop white mater injury and worse neurodevelopmental
outcomes at 15 months (Chow et al., 2005)
+
MMP-9 CSF ↑ PHVD (Okamoto et al., 2008) +
↓ Lower concentration in neonates with PHVD that required shunt (Okamoto et al., 2008) +++
PAI-1 CSF ↑ PHVD (Hansen et al., 2000) +
Highest concentration observed in neonates that required shunt (Hansen et al., 2000) ++
GFAP and NFL CSF ↑ PHVD (Whitelaw et al., 2001) +
Table 1 provides a summary of potential biomarkers.These biomarkers have been detected in blood, urine, and cerebrospinal fluid (CSF). Usefulness of the biomarkers:
(+) limited use because CSF samples are required, (++) very useful but can be altered by other factors such as gestational age and intrauterine growth restriction,
(+++) useful because it may foster different therapy discussion (such shunt placement in patients with PHVD) although required CSF sample.
congenital heart disease requiring surgery acquire PVL (Galli et al.,
2004).
Diagnosis of PVL has been limited to later stages of PVL
where radiological changes are visible in ultrasound or brain MRI.
There is a paucity of publications on PVL serum biomarkers.
Recent research done on autopsy of premature newborns with
PVL has lead to the discovery of immunomarkers of early stages
of PVL and could change our understanding of its physiopathol-
ogy and prevalence. Some of the new described tissue biomarkers
of PVL are:
Human beta-amyloid precursor protein (β-APP) is marker
of wide diffuse axonal damage for early stages of PVL (Arai
et al., 1995; Hirayama et al., 2001) and Fractin that is an apop-
totic marker (Haynes et al., 2008). β-APP and fractin could
improve understand the pathogenesis of diffuse axonal dam-
age in PVL, including whether or not this damage results
in irreversible axonal loss and impaired neuronal function.
There is a paucity of publications on biomarkers of PVL,
an area on increasing interest due to its high frequency in
extremely premature neonates and infants with congenital heart
disease.
SUMMARY
We found that some of the most promising biomarkers for IVH
are S100β and Activin. PHVD biomarkers like TGF-β1, MMP-9,
and PAI-1, could be used to discriminate patients that will require
shunt. We summarized the characteristic of the biomarkers and its
potential usefulness in Tables 1 and 2. There is a paucity of pub-
lications that validated the potential biomarkers of brain injury
with more accurate brain damage assessment, such as brain MRI.
In addition potential biomarkers should explore their correlation
with functional brain outcomes such as amplitude integrated EEG,
full EEG, functional brain MRI, and long term neurodevelopmen-
tal follow-up. The available data indicate that such studies are
not only justified but also urgently needed to care for newborns,
especially those with extreme prematurity.
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